{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-100245","form_type":"8-K","ticker":"ELOX","cik":"0001035354","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2022-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.710427+00:00","generated_at":"2026-06-23T09:17:25.148701+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Eloxx Phase 2 ELX-02 CF trial misses efficacy endpoints; lung exposure low","bullets":["Combination of ELX-02 with ivacaftor did not achieve statistical significance for changes in SCC or FEV1.","ELX-02 was well tolerated; no treatment-related serious adverse events reported.","Evidence of activity seen in patients with higher baseline sweat chloride (p=0.00013 at Day 35).","Steady-state lung drug levels averaged 2 µM, only 20% of lowest preclinical active concentration.","Company plans to start proof-of-concept trial for ELX-02 in Alport syndrome later in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-100245","json":"https://secwatch.observer/filing/0001104659-22-100245.json","markdown":"https://secwatch.observer/filing/0001104659-22-100245.md","text":"https://secwatch.observer/filing/0001104659-22-100245.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000110465922100245/0001104659-22-100245-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000110465922100245/tm2225930d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T09:17:25.148701+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}